143 related articles for article (PubMed ID: 25439988)
1. [2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].
Penault-Llorca F; Vincent-Salomon A; MacGrogan G; Roger P; Treilleux I; Valent A; Mathieu MC; Antoine M; Becette V; Bor C; Brabencova E; Charafe-Jauffret E; Chenard MP; Dauplat MM; Delrée P; Devouassoux M; Fiche M; Fondrevelle ME; Fridman V; Garbar C; Genin P; Ghnassia JP; Haudebourg J; Laberge-Le Couteulx S; Loussouarn D; Maran-Gonzalez A; Marcy M; Michenet P; Poulet B; Sagan C; Trassard M; Verriele V; Arnould L; Lacroix-Triki M;
Ann Pathol; 2014 Oct; 34(5):352-65. PubMed ID: 25439988
[TBL] [Abstract][Full Text] [Related]
2. [Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France].
MacGrogan G; Mathieu MC; Poulet B; Penault-Llorca F; Vincent-Salomon A; Roger P; Treilleux I; Valent A; Antoine M; Becette V; Bor C; Brabencova E; Charafe-Jauffret E; Chenard MP; Dauplat MM; Delrée P; Devouassoux M; Fiche M; Fondrevelle ME; Fridman V; Garbar C; Genin P; Ghnassia JP; Haudebourg J; Laberge-Le Couteulx S; Loussouarn D; Maran-Gonzalez A; Marcy M; Michenet P; Sagan C; Trassard M; Verriele V; Arnould L; Lacroix-Triki M;
Ann Pathol; 2014 Oct; 34(5):366-72. PubMed ID: 25439989
[TBL] [Abstract][Full Text] [Related]
3. [2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France].
Franchet C; Djerroudi L; Maran-Gonzalez A; Abramovici O; Antoine M; Becette V; Berghian A; Blanc-Fournier C; Brabencova E; Charafe-Jauffret E; Chenard MP; Dauplat MM; Delrée P; Duprez-Paumier R; Fleury C; Ghnassia JP; Haudebourg J; Leroux A; MacGrogan G; Mathieu MC; Michenet P; Penault-Llorca F; Poulet B; Robin YM; Roger P; Russ E; Tixier L; Treilleux I; Valent A; Verriele V; Vincent-Salomon A; Arnould L; Lacroix-Triki M;
Ann Pathol; 2021 Nov; 41(6):507-520. PubMed ID: 34393014
[TBL] [Abstract][Full Text] [Related]
4. [Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].
Penault-Llorca F; Vincent-Salomon A; Bellocq JP; Matthieu MC; Grogan GM; Treilleux I; Ettore F; Laberge-Le Couteulx S; Sigal B; Couturier J; Lacroix-Triki M; Antoine M; Balaton A; Baranzelli MC; Becette V; Blanc-Fournier C; Bibeau F; Brabencova E; Croce S; Fridman V; Génin P; Ghnassia JP; Jacquemier J; Poulet B; Roger P; Sagan C; Tas P; Trassard M; Verriele V; Arnould L;
Ann Pathol; 2010 Oct; 30(5):357-73. PubMed ID: 21055523
[TBL] [Abstract][Full Text] [Related]
5. HER2 testing: current status and future directions.
Perez EA; Cortés J; Gonzalez-Angulo AM; Bartlett JM
Cancer Treat Rev; 2014 Mar; 40(2):276-84. PubMed ID: 24080154
[TBL] [Abstract][Full Text] [Related]
6. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
Schalper KA; Kumar S; Hui P; Rimm DL; Gershkovich P
Arch Pathol Lab Med; 2014 Feb; 138(2):213-9. PubMed ID: 24164555
[TBL] [Abstract][Full Text] [Related]
7. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
8. HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.
Advani PP; Crozier JA; Perez EA
Biomark Med; 2015; 9(1):35-49. PubMed ID: 25605454
[TBL] [Abstract][Full Text] [Related]
9. The New Equivocal: Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines.
Long TH; Lawce H; Durum C; Moore SR; Olson SB; Gatter K; Troxell ML
Am J Clin Pathol; 2015 Aug; 144(2):253-62. PubMed ID: 26185310
[TBL] [Abstract][Full Text] [Related]
10. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
Mentrikoski MJ; Stoler MH
Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
[TBL] [Abstract][Full Text] [Related]
11. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
[TBL] [Abstract][Full Text] [Related]
12. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer.
Jensen JD; Knoop A; Ewertz M; Laenkholm AV
Breast Cancer Res Treat; 2012 Apr; 132(2):511-21. PubMed ID: 21667123
[TBL] [Abstract][Full Text] [Related]
13. [Internal quality control on HER2 status determination in breast cancers: Experience of a cancer center].
Ngo C; Laé M; Ratour J; Hamel F; Taris C; Caly M; Le Cunff A; Reyal F; Kirova Y; Pierga JY; Vincent-Salomon A
Bull Cancer; 2017; 104(7-8):608-617. PubMed ID: 28595742
[TBL] [Abstract][Full Text] [Related]
14. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies.
Lebeau A; Turzynski A; Braun S; Behrhof W; Fleige B; Schmitt WD; Grob TJ; Burkhardt L; Hölzel D; Jackisch C; Thomssen C; Müller V; Untch M
J Clin Oncol; 2010 Jul; 28(20):3264-70. PubMed ID: 20498397
[TBL] [Abstract][Full Text] [Related]
15. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
Bethune GC; Veldhuijzen van Zanten D; MacIntosh RF; Rayson D; Younis T; Thompson K; Barnes PJ
Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.
Baehner FL; Achacoso N; Maddala T; Shak S; Quesenberry CP; Goldstein LC; Gown AM; Habel LA
J Clin Oncol; 2010 Oct; 28(28):4300-6. PubMed ID: 20697093
[TBL] [Abstract][Full Text] [Related]
17. Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer.
Xu B; Shen J; Guo W; Zhao W; Zhuang Y; Wang L
Pathol Res Pract; 2019 Feb; 215(2):251-255. PubMed ID: 30420102
[TBL] [Abstract][Full Text] [Related]
18. [Impact of 2013 American Society of Clinical Oncology/College of American Pathologist guidelines on borderline immunostaining results for HER2: a retrospective study on HER2 FISH results in 1 780 cases of invasive breast cancers].
Xu Y; Bai QM; Yang F; Zhu XL; Lu YM; Zhang J; Yang WT; Zhou XY
Zhonghua Bing Li Xue Za Zhi; 2016 Aug; 45(8):545-9. PubMed ID: 27510780
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.
Ross JS
Drug News Perspect; 2009 Mar; 22(2):93-106. PubMed ID: 19330168
[TBL] [Abstract][Full Text] [Related]
20. Justification of the change from 10% to 30% for the immunohistochemical HER2 Scoring criterion in breast cancer.
Liu YH; Xu FP; Rao JY; Zhuang HG; Luo XL; Li L; Luo DL; Zhang F; Xu J
Am J Clin Pathol; 2009 Jul; 132(1):74-9. PubMed ID: 19864236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]